Study type: In vivo/preclinical · Status: Verified against declared source
MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis
2024
Study scale: Male C57BL/6 mice (aged 6‒10 weeks, weighing 20‒25 g) were obtained from the Experimental Animal Center of Xuzhou Medical University and were raised in cages in an air filtration system.
Abstract only: Open source record
Product or molecular entity relationships
- MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Not reported in the reviewed source.
Methods
MOTS-c was synthesized by a standard Fmoc-based solid phase synthesis methodology as described in our previous report [26].
Scale or participants
Male C57BL/6 mice (aged 6‒10 weeks, weighing 20‒25 g) were obtained from the Experimental Animal Center of Xuzhou Medical University and were raised in cages in an air filtration system.
Key findings
Bone cancer pain (BCP), due to cancer bone metastasis and bone destruction, is a common symptom of tumors, including breast, prostate, and lung tumors.
Limitations and uncertainty
Bone cancer pain (BCP), due to cancer bone metastasis and bone destruction, is a common symptom of tumors, including breast, prostate, and lung tumors.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.